Reviews

Contemporary management of small renal tumors


 

The incidence of kidney cancer in the United States is rising because the increased use of cross-sectional imaging is resulting in more tumors being detected and because the population is aging. In addition, a stage migration in kidney cancer has been observed, again because of improved detection, with an increase in stage T1 tumors and a concomitant decrease in the number of stage T2 to T4 tumors. Recent studies have shown that up to 80% of small renal tumors (SRTs) either have an indolent course or are histologically benign. These findings raise the question of what the optimal management of SRTs should be. Radical nephrectomy, the traditional, most aggressive, and still most frequently used extirpative surgery, has been shown to increase the risk of chronic kidney disease. Therefore, during the past 2 decades there has been a shift toward nephron-sparing surgery in carefully selected patients as such procedures have demonstrated equivalent oncologic outcomes with a decrease in long-term renal-induced morbidities.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

ASCO 2014: Dr. Walter M. Stadler gives his top picks in genitourinary research
MDedge Hematology and Oncology
PSA flare after initiation of abiraterone acetate
MDedge Hematology and Oncology
Circumcision may cut prostate cancer risk in black men
MDedge Hematology and Oncology
Drug combo extends survival by more than 1 year in metastatic prostate cancer patients
MDedge Hematology and Oncology
VIDEO: Adding docetaxel up front improved survival in prostate cancer by more than a year
MDedge Hematology and Oncology
Dogs detect prostate cancer VOCs in urine
MDedge Hematology and Oncology
PREVAIL: Enzalutamide benefits patients with visceral and nonvisceral disease
MDedge Hematology and Oncology
Checkpoint inhibitors produce durable responses in metastatic RCC
MDedge Hematology and Oncology
Adding age to stage better predicts adrenocortical carcinoma prognosis
MDedge Hematology and Oncology
Targeted sessions for targeted therapies at ASCO
MDedge Hematology and Oncology